Details checkedStatus confirmedHistorical/discontinuedCheckedpublication

DB-020 by Regeneron and Decibel

Also known as: DB-020, sodium thiosulfate formulation DB-020

Regeneron Pharmaceuticals

Primary source

Company

Regeneron Pharmaceuticals

Program Type

Therapeutic

Modality

Drug Delivery

Stage

Phase 1

Status

Completed

Target Gene

—

Route / Mode

Intratympanic injection

Confidence

92%

Status Confidence

Status confirmed

Evidence Strength

Needs more support

Last Reviewed

2026-05-31

Geography

Australia, United States

Population

adult, cisplatin-ototoxicity

Trial IDs

Mechanism

Locally delivered thiosulfate formulation is injected through the eardrum to inactivate cisplatin in the cochlea while minimizing systemic tumor-protection risk.

Indications

Cisplatin-Induced Hearing Loss Hearing Loss

Notes

One of the strongest non-approved cisplatin-otoprotection assets; randomized intrapatient Phase Ib data materially de-risked local cochlear neutralization as a strategy.

Evidence & Sources

3 structured sources

clinicaltrials

Supports: canonicalName, aliases, trialIds, route, populationTags, geography

IDs: NCT04262336

Open

publication

Supports: mechanism, indications, stage, status, notes

IDs: 40403227

Open

regulatory

Supports: mechanism, notes